StockData

BioCryst Pharmaceuticals vs Exelixis

BCRX and EXEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and EXEL compare

Exelixis is the larger company, worth 8.7 times as much as BioCryst Pharmaceuticals ($16.7B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 9.1% for Exelixis).

Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with −40.9% at BioCryst Pharmaceuticals.

Exelixis scores higher on the StockData Score (18 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXEXEL
Size and price
Market cap$1.9B$16.7B
Share price$7.50$68.50
Change, 1 year5.9%64.5%
Change, 5 years−39.9%302%
Beta (5Y)0.580.32
Employees4351,077
StockData Score
Total score918 (better)
Valuation score13 (better)
Growth score4 (better)3
Performance score26 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–20.5×
P/S2.0× (better)6.7×
P/B–9.1×
EV/EBITDA–15.3×
P/FCF5.1× (better)14.4×
PEG–0.29
FCF yield19.5% (better)6.9%
Fair value–$66.21
Margin of safety–−3.5%
Growth
Revenue growth (TTM)68.7% (better)9.1%
Revenue growth, 5Y average118% (better)18.6%
Net income growth (TTM)–30.6%
EPS growth (TTM)–40.9%
EPS growth, 5Y average–51.4%
Profitability
Gross margin97.8% (better)96.3%
Operating margin−33.3%40.2% (better)
Net margin−40.9%35.5% (better)
FCF margin39.7%46.5% (better)
Return on equity–44.3%
Return on invested capital–75.0%
Financial health
Debt / equity–0.00
Interest coverage−4.2×–
Current ratio2.323.21 (better)
Altman Z-score−3.8317.36 (better)
Piotroski F-score77
Dividends and buybacks
Buyback yield–7.5%
Shareholder yield0.00%7.5% (better)
Ownership
Held by institutions103%106%
Held by insiders1.9%9.0%
Insider net buying, 12 months−$4.1M (better)−$31.8M
Short interest, % of float11.0%11.5%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.